Aclaris Therapeutics, Inc. ACRS 深 沪
等待开盘 11-12 09:30:00 美东时间
4.34
+0.190
+4.58%
华盛通- 最 高4.40
- 今 开4.14
- 成交量 198.11万股
- 最 低 4.08
- 昨 收 4.15
- 总市值 6.88亿
- 52周最高 6.5999
- 市盈率 静 --
- 换手率 1.25%
- 52周最低 2.46
- 委 比 16.10%
- 总股本 1.59亿
- 历史最高 33.88
- 量 比 0.87
- 振 幅 7.71%
- 历史最低 0.5902
- 每 手 1
- 风险率 1.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclaris Therapeutics收跌2.12%，成交额581.01万美元
11月11日，Aclaris Therapeutics（ACRS）收跌2.12%，报4.15美元，成交额581.01万美元，市值6.58亿美元。 行情数据 •...
11-11 06:56
Aclaris Therapeutics 2026财年第3季度营收148.1万美元，同比下降55.11%
最新财报显示，Aclaris Therapeutics 2026财年第3季度实现： 营业收入：148.1万美元 同比：下降55.11% 净利润：-1851万美元...
11-07 08:00
Aclaris Therapeutics Q3 EPS $(0.12) Beats $(0.16) Estimate, Sales $1.481M Beat $1.298M Estimate
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.481 million which beat the analyst consensus estimate of ...
11-05 20:22
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics announced positive results from Phase 1b trials of ATI-052 in atopic dermatitis (AD) and asthma, with significant improvements in skin and lung function. The company expects to initiate a Phase 2b trial for modzatinib in lichen planus in Q4 2026 and anticipates top-line results for bosakitug in AD by year-end. Aclaris has strong cash reserves to support development through H1 2029.
11-05 11:59
Aclaris Therapeutics收跌4.28%，成交额630.54万美元
11月3日，Aclaris Therapeutics（ACRS）收跌4.28%，报3.8美元，成交额630.54万美元，市值5.59亿美元。 行情数据 • 开盘...
11-03 07:01
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Wedbush Maintains Outperform on Aclaris Therapeutics, Lowers Price Target to $8
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and lowers the price target from $10 to $8.
10-28 22:02
Aclaris Therapeutics Announces New $46.7M Equity Offering
An announcement from Aclaris Therapeutics ( ($ACRS) ) is now available. On Octo...
10-28 05:49
Whirlpool Posts Downbeat Q3 Results, Joins HSBC, Hilton Hotels And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining over 150 points on Tuesday. Shares of Whirlpool Corp (NYSE:WHR) fell sharply in pre-market trading after the company reported worse-than-expected third-quarter financial results and cut its FY26 guidance below estimates. Whirl...
10-27 20:02
Aclaris Therapeutics Prices $50M Offering Of 7,785,714 Shares And Warrants To Purchase 6.5M Shares At $3.50/Unit
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share and, in ...
10-27 18:47
